UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases

SAN FRANCISCO – December 23, 2020 – UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients. “The BridgeBio team is developing close relationships with our investigators at UCSF with the mission of bringing potential […]

BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease

Contour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise Partnership Focused on Delivering Targeted Therapies for Genetically Defined Cardiovascular Diseases PALO ALTO and SOUTH SAN FRANCISCO, Dec. 7, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Maze Therapeutics today announced the establishment of a joint venture, Contour Therapeutics, focused on transforming […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Palo Alto, CA, December 4, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on December 1, 2020, the compensation committee of BridgeBio’s board of directors granted 15 new employees options to purchase an aggregate of 15,351 shares of the Company’s common stock with a per […]

BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma

Application accepted under Priority Review designation Application accepted into Real Time Oncology Review (RTOR) pilot program This is BridgeBio’s second NDA acceptance Application will also be submitted for review in Australia and Canada under Project Orbis PALO ALTO, CA – December 1, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company founded to […]